Abstract: Prostate cancer is currently the fifth leading cause of death in men. Now immunotherapy is used as a new paradigm of prostate treatment, where the therapeutic response is aimed at the role of Tumor Infiltrating Lymphocytes (TILs). Anaplastic Lymphoma Kinase (ALK) gene fusion has found in several types of malignancies has been clinically proven to demonstrate an effective therapeutic target response for patients with positive ALK. Currently, combination therapy continues to be developed, especially in cases of recurrence and metastasis, so it is necessary to research on prostate adenocarcinoma.